India’s PharmNXT Biotech targets the global bioprocessing market with cost-effective innovation
As global demand for biologics rises, pharmaceutical manufacturing is undergoing a structural shift. Biologic drugs, including monoclonal antibodies, vaccines, and advanced therapies, are expected to account for nearly 35–40 percent of the global pharmaceuticals market by 2030, according to IQVIA. At the same time, rising costs in the United States and Europe, along with supply disruptions during the COVID-19 pandemic, have accelerated the need for more diversified and resilient manufacturing ecosystems.
Government launches Rs 10,000 Cr Biopharma Shakti Programme to strengthen sector
A Rs 10,000-crore push aims to build India’s biopharma and advanced manufacturing capabilities as disease patterns and technology priorities shift.
Budget 2026: Rs10,000 crore Biopharma Shakti push to make India a biologics hub
The biopharma initiative focuses on boosting biologics production, modernising pharma education, expanding accredited clinical trial sites and elevating drug regulation standards
PharmNXT expects integration of DTR to help both domestic and international markets
Mumbai-based biotech start up PharmNXT Biotech is expecting its integration of Ireland-based modular tubing solutions firm Defined Tubing Routing (DTR), the acquisition it announced in mid 2025, to help expansion of its business not only in India, but also in the international markets.
PharmNXT Biotech Bags ‘Top Emerging Biotech Company’ Award for Sustainable SUT Innovation
PharmNXT Biotech, a fast-growing biotechnology company specialising in sustainable single-use technologies (SUTs), has been named the ‘Top Emerging Biotech Company’ at the BioSpectrum India Excellence Awards 2025.
How Emerging Biotech Startups Reshaping the Bioprocessing Future
In an interaction with Thiruamuthan, Assistant Editor of India Pharma Outlook, Ankush Kapoor, Founder & CEO of PharmNXT Biotech, discusses how India’s biotech ecosystem is redefining bioprocessing through Single-Use Technologies, Defined Tubing Routing, and digital innovation. These advancements are enhancing scalability, sustainability, and compliance while significantly reducing energy, water use, and contamination risks. Startups are increasingly adopting modular, AI-driven, and continuous systems to overcome resource constraints, advance cell and gene therapy production, and position India as a global hub for efficient, sustainable, and technologically advanced biomanufacturing.
How India Can Catch the Next Wave of Growth in Biosimilars, Biologics. and Vaccines
Pharma Industrial India Magazine – September – October
PharmNXT Acquires DTR to Bring European Bioprocess Manufacturing Expertise to India
In a major boost to India’s biopharmaceutical manufacturing landscape, Pune-based startup PharmNXT Biotech has acquired Ireland-based Defined Tubing Routing (DTR), a globally recognised innovator in advanced bioprocess tubing solutions. The strategic acquisition gives PharmNXT direct access to cutting-edge technology in single-use systems, significantly enhancing its ability to deliver customised, high-compliance solutions for pharmaceutical and biopharma clients.
PharmNXT acquires DTR, brings European bioprocess engineering to India
PharmNXT Biotech has acquired Defined Tubing Routing (DTR), a player from Ireland, working in advanced bioprocess tubing solutions. This move enables PharmNXT to access technology solutions related to single-use systems. With the addition of DTR’s modular tubing systems, capable of supporting bioprocess volumes from 20 L to 500 L and custom spans up to 2.9 meters, PharmNXT expands its engineering capabilities, faster turnaround, enhanced customisation, and stronger compliance.
PharmNXT brings European Bioprocess Engineering to India with strategic acquisition of DTR
This move enables PharmNXT to access technology solutions related to single-use systems, strengthening its capacity to serve pharmaceutical and biopharma clients with more tailored and technically aligned offerings. With the addition of DTR’s modular tubing systems, capable of supporting bioprocess volumes from 20 L to 500 L and custom spans up to 2.9 meters, PharmNXT significantly expands its engineering capabilities, faster turnaround, enhanced customisation, and stronger compliance.